Logo image of ABCL

ABCELLERA BIOLOGICS INC (ABCL) Stock Fundamental Analysis

USA - NASDAQ:ABCL - CA00288U1066 - Common Stock

5.385 USD
-0.17 (-2.97%)
Last: 11/3/2025, 12:55:35 PM
Fundamental Rating

4

Overall ABCL gets a fundamental rating of 4 out of 10. We evaluated ABCL against 58 industry peers in the Life Sciences Tools & Services industry. While ABCL has a great health rating, there are worries on its profitability. ABCL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ABCL has reported negative net income.
In the past year ABCL has reported a negative cash flow from operations.
In multiple years ABCL reported negative net income over the last 5 years.
In multiple years ABCL reported negative operating cash flow during the last 5 years.
ABCL Yearly Net Income VS EBIT VS OCF VS FCFABCL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M -300M

1.2 Ratios

With a Return On Assets value of -11.82%, ABCL perfoms like the industry average, outperforming 44.83% of the companies in the same industry.
ABCL has a Return On Equity of -16.45%. This is comparable to the rest of the industry: ABCL outperforms 50.00% of its industry peers.
Industry RankSector Rank
ROA -11.82%
ROE -16.45%
ROIC N/A
ROA(3y)-3.84%
ROA(5y)2.39%
ROE(3y)-5.09%
ROE(5y)2.8%
ROIC(3y)N/A
ROIC(5y)N/A
ABCL Yearly ROA, ROE, ROICABCL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABCL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABCL Yearly Profit, Operating, Gross MarginsABCL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

8

2. Health

2.1 Basic Checks

ABCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ABCL has more shares outstanding
The number of shares outstanding for ABCL has been increased compared to 5 years ago.
There is no outstanding debt for ABCL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ABCL Yearly Shares OutstandingABCL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
ABCL Yearly Total Debt VS Total AssetsABCL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 2.50 indicates that ABCL is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of ABCL (2.50) is better than 60.34% of its industry peers.
There is no outstanding debt for ABCL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.5
ROIC/WACCN/A
WACC9.7%
ABCL Yearly LT Debt VS Equity VS FCFABCL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

ABCL has a Current Ratio of 11.07. This indicates that ABCL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ABCL (11.07) is better than 93.10% of its industry peers.
A Quick Ratio of 11.07 indicates that ABCL has no problem at all paying its short term obligations.
ABCL's Quick ratio of 11.07 is amongst the best of the industry. ABCL outperforms 93.10% of its industry peers.
Industry RankSector Rank
Current Ratio 11.07
Quick Ratio 11.07
ABCL Yearly Current Assets VS Current LiabilitesABCL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for ABCL have decreased by -1.85% in the last year.
The Revenue has decreased by -0.54% in the past year.
ABCL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.97% yearly.
EPS 1Y (TTM)-1.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
Revenue 1Y (TTM)-0.54%
Revenue growth 3Y-57.48%
Revenue growth 5Y19.97%
Sales Q2Q%133.29%

3.2 Future

ABCL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.51% yearly.
The Revenue is expected to grow by 44.86% on average over the next years. This is a very strong growth
EPS Next Y-13.13%
EPS Next 2Y-3.46%
EPS Next 3Y-9.99%
EPS Next 5Y21.51%
Revenue Next Year4.72%
Revenue Next 2Y30.62%
Revenue Next 3Y13.19%
Revenue Next 5Y44.86%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ABCL Yearly Revenue VS EstimatesABCL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ABCL Yearly EPS VS EstimatesABCL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABCL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABCL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABCL Price Earnings VS Forward Price EarningsABCL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABCL Per share dataABCL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

ABCL's earnings are expected to decrease with -9.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.46%
EPS Next 3Y-9.99%

More info and screens

0

5. Dividend

5.1 Amount

ABCL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABCELLERA BIOLOGICS INC

NASDAQ:ABCL (11/3/2025, 12:55:35 PM)

5.385

-0.17 (-2.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06/amc
Inst Owners37.34%
Inst Owner Change-1.61%
Ins Owners4.15%
Ins Owner Change0%
Market Cap1.61B
Revenue(TTM)32.88M
Net Income(TTM)-165665000
Analysts82.86
Price Target9.47 (75.86%)
Short Float %23.45%
Short Ratio10.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.78%
Min EPS beat(2)-3.56%
Max EPS beat(2)29.13%
EPS beat(4)2
Avg EPS beat(4)11.38%
Min EPS beat(4)-9.89%
Max EPS beat(4)29.86%
EPS beat(8)5
Avg EPS beat(8)9.38%
EPS beat(12)7
Avg EPS beat(12)-133.65%
EPS beat(16)8
Avg EPS beat(16)-102.67%
Revenue beat(2)1
Avg Revenue beat(2)64.43%
Min Revenue beat(2)-44.84%
Max Revenue beat(2)173.69%
Revenue beat(4)1
Avg Revenue beat(4)18.6%
Min Revenue beat(4)-44.84%
Max Revenue beat(4)173.69%
Revenue beat(8)2
Avg Revenue beat(8)-1.11%
Revenue beat(12)3
Avg Revenue beat(12)-4.7%
Revenue beat(16)5
Avg Revenue beat(16)-4.78%
PT rev (1m)0%
PT rev (3m)1.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.17%
EPS NY rev (1m)0%
EPS NY rev (3m)8.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)56.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 48.95
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.75
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.11
BVpS3.37
TBVpS3.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.82%
ROE -16.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-3.84%
ROA(5y)2.39%
ROE(3y)-5.09%
ROE(5y)2.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 96.45%
Cap/Sales 176.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.07
Quick Ratio 11.07
Altman-Z 2.5
F-Score4
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)221.53%
Cap/Depr(5y)274.86%
Cap/Sales(3y)163.57%
Cap/Sales(5y)102.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
EPS Next Y-13.13%
EPS Next 2Y-3.46%
EPS Next 3Y-9.99%
EPS Next 5Y21.51%
Revenue 1Y (TTM)-0.54%
Revenue growth 3Y-57.48%
Revenue growth 5Y19.97%
Sales Q2Q%133.29%
Revenue Next Year4.72%
Revenue Next 2Y30.62%
Revenue Next 3Y13.19%
Revenue Next 5Y44.86%
EBIT growth 1Y-3.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.64%
EBIT Next 3Y3.49%
EBIT Next 5YN/A
FCF growth 1Y26.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.63%
OCF growth 3YN/A
OCF growth 5YN/A

ABCELLERA BIOLOGICS INC / ABCL FAQ

What is the ChartMill fundamental rating of ABCELLERA BIOLOGICS INC (ABCL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ABCL.


What is the valuation status of ABCELLERA BIOLOGICS INC (ABCL) stock?

ChartMill assigns a valuation rating of 0 / 10 to ABCELLERA BIOLOGICS INC (ABCL). This can be considered as Overvalued.


Can you provide the profitability details for ABCELLERA BIOLOGICS INC?

ABCELLERA BIOLOGICS INC (ABCL) has a profitability rating of 1 / 10.


Can you provide the financial health for ABCL stock?

The financial health rating of ABCELLERA BIOLOGICS INC (ABCL) is 7 / 10.